Five-year effects of nasal continuous positive airway pressure in obstructive sleep apnoea syndrome

A. Chaouat, E. Weitzenblum, R. Kessler, M. Oswald, E. Sforza, M-N. Liegeon, J. Krieger


ABSTRACT: There have been very few studies assessing the long-term physiological effects of nasal continuous positive airway pressure (CPAP) for the obstructive sleep apnoea syndrome. We therefore investigated prospectively the evolution of lung function, arterial blood gases and pulmonary haemodynamics in patients with this syndrome treated with CPAP. Sixty five patients were included. The mean duration of home treatment with nasal CPAP was 64±6 months. Most of the patients (77%) were smokers at the baseline assessment.

We observed a small, but significant, decrease in forced expiratory volume in one second (FEV1) from 80±21% at baseline (t0) to 76±21% of the predicted value at the follow-up evaluation (t5) (p<0.01). Arterial oxygen tension (Pao2) for the group as a whole remained stable (9.4±1.5 kPa (71±11 mmHg) versus 9.4±1.2 kPa (71±9 mmHg)). However, Pao2 increased in the subgroup of patients with hypoxaemia at t0 (n=23), from 7.8±0.7 kPa (59±5 mmHg) to 8.9±1.2 kPa (67±9 mmHg).

Arterial carbon dioxide tension (Paco2) for the group as a whole increased slightly, but significantly, from 5.2±0.7 kPa (39±5 mmHg) to 5.4±0.5 kPa (41±4 mmHg) (p<0.05). Mean pulmonary artery pressure (Ppa) at rest did not change (16±5 mmHg versus 17±5 mmHg; NS) nor did exercising Ppa. In the 11 patients with pulmonary hypertension at t0, Ppa was 24±5 mmHg at t0 versus 20±7 mmHg at t5 (NS).

We conclude that the significant decrease of forced expiratory volume in one second after 5 yr follow-up was related to a high percentage of smokers and exsmokers in the study population. Daytime arterial oxygen tension and pulmonary artery pressure remained stable in an unselected series of 65 obstructive sleep apnoea syndrome patients treated for 5 yrs with nasal continuous positive airway pressure, unlike arterial carbon dioxide tension, which increased by a small, but significant, amount.


Since the original publication by SULLIVAN et al. [1], there has been considerable development of treatment with nasal continuous positive airway pressure (CPAP) in patients with the obstructive sleep apnoea syndrome (OSAS). However, there have been very few studies devoted to the long-term physiological effects of this treatment [2–4].

The evolution of lung function and arterial blood gases, particularly in those patients who are hypoaxemic, hypercapnic and have pulmonary hypertension at the beginning of treatment with nasal CPAP is not well appreciated. In 1990 we reported that nasal CPAP improved hypoxaemia and hypercapnia [2]. The same study also showed that pulmonary haemodynamics did not change in these patients. However, the duration of follow-up was limited to a mean of 18 months, whereas at the time of the present study some patients have been receiving treatment for more than 10 yrs.

Thus, the aim of the present study was to investigate prospectively the evolution of lung function, arterial blood gases and pulmonary haemodynamics in a series of unselected obstructive sleep apnoea patients who were followed for 5 yrs. No similar study has been reported beyond a follow-up of 18 months.

Patients and methods

The eligible population consisted of patients referred to our Sleep Disorders Unit with a suspected diagnosis of OSAS. The inclusion criteria were the polysomnographic demonstration of 20 or more apnoeas per hour of sleep (>80% of them being of obstructive type) and the acceptance of home treatment with nasal CPAP. Spirometry and arterial blood gas measurements were performed in all patients before starting nasal CPAP. Patients were asked to undergo right heart catheterization provided that there was no contra-indication. After approximately 5 yrs (range 60–71 months) of home treatment with nasal CPAP, all patients underwent follow-up evaluation including spirometry and arterial blood gas measurement. Right heart catheterization after 5 yrs of follow-up was proposed to patients who underwent it initially. All catheterized patients gave
informed consent. Investigation was not performed during an acute exacerbation of respiratory disease (pulmonary infection, acute bronchitis, episode of right heart failure or acute respiratory failure) and the time between any such episode and the day of investigation was at least 6 weeks.

Polysomnography was performed during two consecutive nights, without (diagnostic night) and with CPAP, as part of the baseline evaluation. The method has been described elsewhere [2]. Briefly, the polygraphic sleep recording included standard electro-encephalograph, electro-oculograph, and electromyogram of chin muscles. Breathing during sleep was analysed with a Fleisch No. 2 pneumotachograph (Godart, Statham Instruments, Oxnard, CA, USA) attached to a soft Silastic facial mask (No. 3434, Bird Corp, Palm Springs, CA, USA), and by means of either thoracic and abdominal mercury-filled strain gauges or an oesophageal balloon. Transcutaneous oxygen saturation was recorded with a pulse oximeter (Biox III, Ohmeda, Louisville, CO, USA). Central, obstructive and mixed apnoeas were defined according to usual criteria [5]. Hypopnoeas were defined as a 50% fall of tidal volume from its value during quiet wakefulness, for at least 10 s, without a major change in respiratory rate.

Conventional spirometry was performed with a 10 L closed-circuit spiropigraph. Static lung volumes were measured by the closed-circuit helium dilution method. Reference values were those of the European Respiratory Society [6].

Right heart catheterization was performed as previously described [7]. Briefly, the haemodynamic measurements were always done while the patient was awake, in the supine position. For the purpose of this study we used small diameter floated catheters, either Grandjean flexoupulmocaths (French size No. 4; Plastimed, Saint-Leu-la-Forêt, France) or Swan-Ganz catheters (French size No. 5; Edwards Lab Inc, Anasco, Puerto Rico). The catheter was introduced percutaneously into an antecubital or femoral vein. Arterial blood gases were measured simultaneously by the closed-circuit helium dilution method. Pulmonary capillary wedge pressure (Pcw) was measurable in 42 patients at t0, but valid measurements were obtained in only 16 patients at both t0 and t5. None of the 65 re-evaluated patients were treated with conventional long-term oxygen therapy (≥16 h daily) during the follow-up. Three were treated with nocturnal oxygen therapy (6–8 h night) in conjunction with nasal CPAP.

Baseline evaluation (t0)

The mean (±SD) age of the 65 patients was 53±10 yrs. Fifty (77%) of the 65 patients were current smokers at t0, of whom 27 (42%) were heavy smokers (>30 pack yrs). The majority of patients were obese: 46 (71%) had a body mass index (BMI) >30 kg·m-2, among whom 16 (25%) had a BMI >35 kg·m-2. The mean (±SD) BMI was 33±6 kg·m-2 at t0.

The results of the baseline polysomnographic data are shown in table 1. They show high values of apnoea and apnoea+hypopnoea index (70±36 and 87±33 events·h-1, respectively). Sleep architecture was severely disturbed, with predominance of sleep stages 1 and 2 and few stages 3 and 4.

### Table 1. Baseline polysomnographic data in the 65 patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1 events·h-1</td>
<td>70</td>
<td>36</td>
</tr>
<tr>
<td>AIHI events·h-1</td>
<td>87</td>
<td>33</td>
</tr>
<tr>
<td>TST min</td>
<td>292</td>
<td>94</td>
</tr>
<tr>
<td>Stages 1 and 2%</td>
<td>90</td>
<td>9</td>
</tr>
<tr>
<td>Stages 3 and 4%</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>REM %</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>S5O2 %</td>
<td>92</td>
<td>5</td>
</tr>
<tr>
<td>S5O2 &lt;90%</td>
<td>24</td>
<td>26</td>
</tr>
</tbody>
</table>

AI: apnoea index; AHI: apnoea+hypopnoea index; TST: total sleep time; REM: rapid eye movement; S5O2: arterial oxygen saturation; S5O2 <90%: time spent with S5O2 <90%.

### Statistical analysis

Values were expressed as the mean±SD. Groups of patients were compared using Mann-Whitney U-test. Baseline (t0) and follow-up (t5) values were compared using Student’s paired t-test or Wilcoxon rank sum test when the number of pairs was less than 30. Rejection of the null hypothesis required a p-value of less than 0.05.

### Results

Between December 1983 and June 1989, 107 patients met the criteria of the present study. During the follow-up, 10 patients died, 29 patients stopped nasal CPAP and three decided to be treated elsewhere. Therefore 65 patients (63 males and two females) were re-evaluated after 5 yrs of home treatment with nasal CPAP. Among these 65 patients, 62 underwent a pulmonary haemodynamic study at t0. Unfortunately, only 44 patients accepted a pulmonary haemodynamic study at t5. Thus, pulmonary artery pressures were compared in 44 patients. Age, lung function, arterial blood gases, sleep parameters and mean pulmonary artery pressure (PAw) at t0 were similar in these 44 patients and in the others who did not undergo right heart catheterization at t5 (data not shown). Pulmonary capillary wedge pressure (Pcw) was measurable in 42 patients at t0, but valid measurements were obtained in only 16 patients at both t0 and t5. None of the 65 re-evaluated patients were treated with conventional long-term oxygen therapy (≥16 h daily) during the follow-up. Three were treated with nocturnal oxygen therapy (6–8 h night) in conjunction with nasal CPAP.
very short periods spent in stages 3 and 4 and rapid eye movement (REM) sleep.

The average value of the forced expiratory volume in one second (FEV1)/vital capacity (VC) ratio was normal (72±10%), whereas VC, FEV1 and total lung capacity (TLC) were at the lower limit of the normal range (table 2). Thirteen (20%) patients had an obstructive spirometric pattern, defined by a FEV1/VC ratio ≤55%. Nineteen (29%) patients, most of whom were markedly obese, had a restrictive ventilatory defect defined as TLC <80% pred. Four (6%) patients had both an obstructive and a restrictive pattern.

The mean arterial oxygen tension (PaO2) for the group as a whole was mildly decreased (9.4±1.5 kPa (71±11 mmHg)) (table 3). Twenty three (35%) patients were initially hypoxaemic, as defined by a PaO2 ≤8.6 kPa (65 mmHg). The average arterial carbon dioxide tension (PaCO2) was normal (5.2±0.7 kPa (39±5 mmHg)) and only eight of the 65 (12%) patients were hypercapnic, as defined by a PaCO2 ≥6.9 kPa (45 mmHg).

The average value of PaO2 for the 44 patients who underwent a comparative pulmonary haemodynamic study was normal (16±5 mmHg). Eleven of the 44 (25%) patients had pulmonary hypertension, defined by a PaO2 ≥20 mmHg. When present, pulmonary hypertension was mild to moderate and PaO2 never exceeded 35 mmHg. The average value of PCw at t0 for the 16 patients in whom it could be measured at t0 and t5 was 6±2 mmHg, ranging 3–16 mmHg.

### Follow-up evaluation (t5)

The 65 patients reported good adaptation to the CPAP equipment. The mean duration of home treatment with nasal CPAP between t0 and t5 was 64±6 months. The average pressure was 10±3 cmH2O during the first year of treatment and 9±2 cmH2O during the remaining time. The mean daily use of CPAP from t0 to t5 was 5.2 h.

Thirty of the 50 smokers at t0 had stopped smoking during the follow-up. BMI increased slightly from 33±6 to 34±6 kg·m−2 (p<0.05) after 5 yrs of home treatment with nasal CPAP.

VC (% pred) and TLC did not change significantly (table 2). Small, but significant, decreases in FEV1 % pred and FEV1/VC ratio were observed. The average values of FEV1 were 2,660±860 mL at t0 versus 2,410±820 mL at t5 (p<0.001) and the mean annual decrease in FEV1 was 48 mL with a large dispersion of individual values (so 74 mL). Twenty six (40%) patients showed an obstructive spirometric pattern (as defined above) at t5 versus 13 (20%) at t0.

PaO2, as a mean value remained stable in the 65 patients who were re-evaluated (table 3). However, PaO2 improved significantly from 7.8±0.7 kPa (59±5 mmHg) to 8.9±1.2 kPa (67±9 mmHg) (p<0.001) in the 23 patients who were hypoxaemic at t0. PaCO2 increased very slightly, but significantly, from 5.2±0.7 kPa (39±5 mmHg) to 5.5±0.5 kPa (41±4 mmHg) (p<0.05) in the group as a whole, but had a tendency to decrease from 6.4±0.4 kPa (48±3 mmHg) to 5.9±0.5 kPa (44±4 mmHg) (p=0.09) in the eight patients who were hypercapnic at t0.

Neither Pa at rest nor Pa during exercise changed significantly (table 3). Concerning the 11 patients who had pulmonary hypertension at t0, the average values of Pa at rest were 24±5 mmHg at t0 versus 20±7 mmHg at t5 (p=0.14). PCw as a mean increased significantly from 6±2 mmHg to 9±3 mmHg (p<0.01) in the 16 patients in whom repeat measurements could be made.

### Discussion

The present study shows that in the group of OSAS patients, including a large number of smokers, FEV1 and FEV1/VC ratio decreased significantly after 5 yrs of home treatment with nasal CPAP. PaO2 remained stable and PaCO2 increased slightly. As regards pulmonary haemodynamics, PaO2 at rest and during exercise remained unchanged.

One hundred and seven patients met all the criteria at the baseline evaluation. From these 107 patients, three chose to be treated elsewhere, 29 stopped nasal CPAP and 10 died. Consequently, 42 patients could not complete the study. Hence, overall less than 10% of patients were lost each year. This disadvantage of prospective longitudinal studies cannot be avoided [8]. Therefore, we believe that the 65 patients included in this study and re-evaluated after 5 yrs of follow-up were reasonably representative of an OSAS population seen at a sleep laboratory. This was confirmed by the similarity between these 65 patients and other series of OSAS patients, with regard to lung function, arterial blood gases and pulmonary haemodynamics [9, 10].

### Table 2. – Anthropometric data and lung function before (t0) and after 5 yrs (t5) of treatment with continuous positive airway pressure (CPAP) in 65 patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>BMI kg·m²</th>
<th>VC mL</th>
<th>VC % pred</th>
<th>FEV1 mL</th>
<th>FEV1 % pred</th>
<th>FEV1/VC %</th>
<th>TLC mL</th>
<th>TLC % pred</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>33±6</td>
<td>3650±910</td>
<td>86±15</td>
<td>2660±860</td>
<td>80±21</td>
<td>72±10</td>
<td>5610±190</td>
<td>86±14</td>
</tr>
<tr>
<td>Follow-up</td>
<td>34±6*</td>
<td>3510±930*</td>
<td>85±16</td>
<td>2410±820***</td>
<td>76±21**</td>
<td>68±11***</td>
<td>5470±1070</td>
<td>84±13</td>
</tr>
</tbody>
</table>

Values are presented as mean±SD. BMI: body mass index; VC: vital capacity; % pred: percentage of predicted value; FEV1: forced expiratory volume in one second; TLC: total lung capacity. *: p<0.05, **: p<0.01, ***: p<0.001 versus baseline (paired t-test).

### Table 3. – Arterial blood gases and pulmonary haemodynamics before (t0) and after 5 yrs (t5) of treatment with continuous positive airway pressure (CPAP)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Pairs</th>
<th>n</th>
<th>Baseline</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO2 mmHg</td>
<td>65</td>
<td>71±11</td>
<td>71±9</td>
<td></td>
</tr>
<tr>
<td>PaCO2 mmHg</td>
<td>65</td>
<td>39±5</td>
<td>41±4*</td>
<td></td>
</tr>
<tr>
<td>Pa rest mmHg</td>
<td>44</td>
<td>16±5</td>
<td>17±5</td>
<td></td>
</tr>
<tr>
<td>PCw mmHg</td>
<td>16</td>
<td>6±2</td>
<td>9±3**</td>
<td></td>
</tr>
<tr>
<td>Pcp exercise mmHg</td>
<td>34</td>
<td>30±9</td>
<td>30±7</td>
<td></td>
</tr>
</tbody>
</table>

Values are presented as mean±SD. PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; Pcp: mean pulmonary artery pressure; PCw: pulmonary capillary wedge pressure. *: p<0.05, **: p<0.01 versus baseline (Wilcoxon or paired t-test). 1 mmHg = 0.133 kPa.
We observed a small but significant decrease in FEV1 and FEV1/VC ratio from $t_0$ to $t_5$. The decrease in FEV1 and FEV1/VC ratio can be explained by the fact that there was a high percentage of smokers at the beginning of the study. For the study as a whole, FEV1 decreased from 2,660 to 2,410 mL during a follow-up of 5 yrs, which corresponds to a mean decrease of approximately 50 mL·yr⁻¹. This is less than the annual decrease in heavy smokers “at risk” [11], but more than the functional evolution of never-smokers. In the latter, FEV1 declines by about 25–30 mL·yr⁻¹ [6]. In heavy smokers, FEV1 decreases more, and different authors have observed variable degrees of worsening of the FEV1. SNIDER et al. [12] reported a decrease of 150 mL·yr⁻¹ in susceptible smokers, whereas a mean decrease of 90 mL·yr⁻¹ was found by BURROWS [13] in COPD patients whose FEV1 was more than 45% of the predicted value. Furthermore, FLETCHER [11] reported that the accelerated decline of FEV1 in smokers usually stops with the cessation of smoking, the decrease of FEV1 being then similar to that observed in nonsmokers. In our series, most of the patients were smokers at the beginning of the study but more than half stopped smoking. Thus, a mean decrease in FEV1 of 50 mL·yr⁻¹ is similar to the expected value. In fact, we observed a similar decrease of FEV1 irrespective of smoking habits. The average annual decreases of FEV1 were 48±74 mL, 44±78 mL and 56±72 mL in the 15 never-smokers, 30 exsmokers and 20 current smokers at $t_5$, respectively. This discrepancy between the present results and the studies quoted above is probably due to the small number of patients in each group, subdivided according to smoking habits, and to the large dispersion of individual values.

Since smoking is a risk factor for both sleep-disordered breathing [14] and COPD, it is not surprising that we observed a high percentage of smokers and a relatively high frequency of associated COPD in our series of OSAS patients. This frequency of associated COPD increased at the follow-up evaluation as FEV1 and FEV1/VC ratio declined with time, which is consistent with a cross-sectional study [15] from our department. Our previous study [15] showed that OSAS patients associated COPD were significantly older than OSAS patients without chronic airway disease. The mean ages were 58±9 and 53±10 yrs, respectively (p=0.01). As a consequence, spirometric measurements should be repeated during the follow-up of OSAS patients who have abnormal or borderline values. However, the most important issue is to ensure smoking cessation in these patients. This may have clinical implications since OSAS patients with associated COPD are at a greater risk of developing respiratory insufficiency and cor pulmonale [9, 15, 16].

In our 65 patients, $P_{a,O_2}$ remained stable and $P_{a,CO_2}$ increased slightly. These results are difficult to interpret for two reasons. Firstly, arterial blood gases evolved in a divergent way in these patients. Indeed, 17 patients exhibited concomitant improvement in $P_{a,O_2}$ and $P_{a,CO_2}$ and 27 exhibited concomitant worsening. On the other hand, $P_{a,O_2}$ and $P_{a,CO_2}$ increased or decreased concomitantly in 21 patients. Second, we did not investigate the ventilatory drive in these patients and measurement of alveolar ventilation and alveolar-arterial partial pressure of oxygen difference were only available in a few patients, respectively. Several reports [4, 17, 18] have shown a decrease of $P_{a,CO_2}$ after long-term use of nasal CPAP in OSAS patients, associated with an increase of ventilatory drive. It should, however, be kept in mind that these reports included a high percentage of severely obese patients; this was not the case of the present study, which is probably more representative of the “general” population of OSAS patients in Europe. As mentioned by KOZHEV et al. [19] the decrease of $P_{a,CO_2}$ after treatment with nasal CPAP is not observed in OSAS patients with associated COPD, and the 65 patients of the present study included a high percentage of such “overlap” patients.

The present data also show that in patients who were hypoxaemic at $t_0$, $P_{a,O_2}$ increased. Since $P_{a,O_2}$ did not increase in the group as a whole, this improvement could be due to regression to the mean. Importantly, however, it is clear that these more severely hypoxaemic patients did not deteriorate when treated with nasal CPAP.

As regards pulmonary haemodynamics we believe that the group of 44 patients in whom $P_{pa}$ could be re-evaluated is representative of the group as a whole. Indeed, as mentioned above, there were no differences in terms of all variables at $t_0$ between these patients and the remainder. In these 44 patients we observed that $P_{pa}$ at rest and during exercise remained unchanged at the follow-up evaluation. FLENLEY [20] first suggested that nocturnal events could potentiate the pulmonary vascular effects of lung disease in the “overlap syndrome”. In a recent study [21] we observed that 37 OSAS patients with pulmonary hypertension diagnosed before starting specific treatment had a mean daytime $P_{a,O_2}$ of 8.5±1.2 kPa (64±9 mmHg), whereas pulmonary hypertension in COPD patients generally occurs with a lower $P_{a,O_2}$, usually <7.3 kPa (55 mmHg). This discordance has been emphasized by several groups [9, 22, 23]. It is probably the result of transient nocturnal hypoxaemia and pulmonary hypertensive peaks. Accordingly one may suppose that suppressing nocturnal events with nasal CPAP in these patients has prevented further increases of $P_{pa}$, particularly in those who had the highest daytime $P_{pa}$ at the onset of the study.

We conclude that the significant decrease of forced expiratory volume in one second after 5 yr follow-up was related to a high percentage of smokers and exsmokers in our population. Daytime arterial oxygen tension and pulmonary artery pressure remained stable in an unselected series of 65 obstructive sleep apnoea syndrome patients treated for 5 yrs with nasal continuous positive airway pressure. This was particularly noteworthy in patients who showed the most abnormal values at the start of the study.

References


